论文部分内容阅读
目的:观察分析西替利嗪联合卡介菌多糖核酸对儿童过敏性紫癜的临床疗效。方法:将我院从2010年1月至2011年10月我院收治的144例儿童过敏性紫癜患者随机平均分为对照组72例,应用以西替利嗪为主的常规治疗,实验组72例在对照组基础上加用卡介菌多糖核酸,治疗持续3周。检测对比治疗前后患者抗体水平,并统计计算治疗有效率;随访6个月,统计复发情况。结果:两组治疗前后血清T细胞和抗体、补体水平变化结果显示,治疗前组间差异无统计学意义(P>0.05);治疗后,实验组CD3、CD4和CD16+56上升程度大于对照组,CD8、CD19、IgA和C3、C4下降程度大于对照组,组间差异有统计学意义(P<0.05);对照组复发率为11.8%(8/68),治疗满意度为85.3%;实验组复发率为5.7%(4/70),治疗满意度为92.9%,组间差异有统计学意义(P<0.05);对照组痊愈32例,显效25例,好转7例,无效4例,治疗有效率为83.8%;实验组痊愈39例,显效27例,好转3例,无效1例,治疗有效率94.3%,组间差异有统计学意义(P<0.05)。结论:西替利嗪联合卡介菌多糖核酸能有效治疗儿童过敏性紫癜,安全高效,值得推广应用。
Objective: To observe the clinical efficacy of cetirizine plus BCG polysaccharide nucleic acid in children with Henoch-Schonlein purpura. Methods: From January 2010 to October 2011 in our hospital, 144 cases of children with Henoch-Schonlein purpura were randomly divided into control group, 72 cases, the application of cetirizine-based conventional treatment, the experimental group of 72 cases In the control group based on the use of BCG polysaccharide nucleic acid therapy for 3 weeks. The levels of antibody in patients before and after treatment were detected and compared. The treatment efficiency was calculated statistically. The patients were followed up for 6 months and the recurrence was analyzed. Results: The changes of serum T cells, antibody and complement level before and after treatment showed no significant difference between the two groups before treatment (P> 0.05). After treatment, the levels of CD3, CD4 and CD16 + 56 in the experimental group increased more than those in the control group (P <0.05). The recurrence rate was 11.8% (8/68) in the control group and the treatment satisfaction rate was 85.3%. The level of CD8, CD19, IgA, C3 and C4 in the control group was significantly lower than that in the control group The recurrence rate was 5.7% (4/70) in treatment group and 92.9% in treatment satisfaction group (P <0.05). In control group, 32 cases were cured, 25 cases were markedly improved, 7 cases improved, 4 cases were ineffective, The cure rate was 83.8%. In the experimental group, 39 cases were cured, 27 cases were markedly effective, 3 cases were improved, 1 was ineffective, and the effective rate was 94.3%. There was significant difference between the two groups (P <0.05). Conclusion: Cetirizine combined with BCG polysaccharides nucleic acid can effectively treat children with Henoch-Schonlein purpura, which is safe and effective and should be widely applied.